ArticleMolecular therapy. Advances2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humans.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge, with considerable morbidity and mortality. Existing hemodynamic drug therapies often cause side effects like hypotension and reflex tachycardia, which can hinder optimal dosing. Relaxin, a pregnancy hormone, stimulates RXFP1 receptors in the kidneys, reducing systemic vascular resistance while increasing renal blood flow and renin release to maintain blood pressure. Prior clinical studies using injectable short- or long-acting relaxin analogues have not delivered sustained benefits. AZD5462, a novel oral small-molecule RXFP1 agonist designed for chronic use, was evaluated in translational studies involving non-human primates (NHPs) with HFrEF and in phase 1 trials in healthy humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.